psilocybin / Silo Pharma - LARVOL DELTA

PDP: Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease (clinicaltrials.gov) - P2 | N=12 | Completed | Sponsor: Joshua Woolley, MD, PhD | Trial completion date: Dec 2023 ➔ Dec 2024 | Trial primary completion date: Dec 2023 ➔ Dec 2024

Trial completion date • Trial primary completion date • CNS Disorders • Depression • Mood Disorders • Movement Disorders • Parkinson's Disease • Psychiatry

PDP: Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease (clinicaltrials.gov) - P2 | N=12 | Completed | Sponsor: Joshua Woolley, MD, PhD | Trial primary completion date: Jun 2023 ➔ Dec 2023

Trial primary completion date • CNS Disorders • Depression • Mood Disorders • Movement Disorders • Parkinson's Disease • Psychiatry

PDP: Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease (clinicaltrials.gov) - P2 | N=12 | Completed | Sponsor: Joshua Woolley, MD, PhD | Active, not recruiting ➔ Completed | Trial completion date: Dec 2024 ➔ Dec 2023 | Trial primary completion date: Apr 2024 ➔ Jun 2023

Trial completion • Trial completion date • Trial primary completion date • CNS Disorders • Depression • Mood Disorders • Movement Disorders • Parkinson's Disease • Psychiatry

PDP: Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease (clinicaltrials.gov) - P2 | N=10 | Active, not recruiting | Sponsor: Joshua Woolley, MD/PhD | Trial completion date: Oct 2023 ➔ Dec 2024 | Trial primary completion date: Oct 2023 ➔ Apr 2024

Trial completion date • Trial primary completion date • CNS Disorders • Depression • Mood Disorders • Movement Disorders • Parkinson's Disease • Psychiatry

PDP: Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease (clinicaltrials.gov) - P2 | N=10 | Active, not recruiting | Sponsor: Joshua Woolley, MD/PhD | Recruiting ➔ Active, not recruiting | Trial completion date: Jun 2023 ➔ Oct 2023 | Trial primary completion date: Jun 2023 ➔ Oct 2023

Enrollment closed • Trial completion date • Trial primary completion date • CNS Disorders • Depression • Mood Disorders • Movement Disorders • Parkinson's Disease • Psychiatry

PDP: Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease (clinicaltrials.gov) - P2 | N=10 | Recruiting | Sponsor: Joshua Woolley, MD/PhD | Trial completion date: Dec 2022 ➔ Jun 2023 | Trial primary completion date: Dec 2022 ➔ Jun 2023

Trial completion date • Trial primary completion date • CNS Disorders • Depression • Mood Disorders • Movement Disorders • Parkinson's Disease • Psychiatry

Silo Pharma Advances Clinical Study Analyzing Effects of Psilocybin on Inflammation (GlobeNewswire) - "Silo Pharma, Inc...today announced a progress update on its sponsored research study with the University of California, San Francisco (UCSF) examining psilocybin’s effect on inflammatory activity in humans. The clinical study evaluates three populations of patients suffering from Parkinson's disease, bipolar disorder, and chronic pain....For each patient population, the clinical studies involve preparation therapy, two separate dosing sessions with psilocybin, and integration therapy. At the Clinical & Translational Science Institute (CTSI) at UCSF, four blood samples are collected from each participant, one at baseline before treatment begins, one at 24 hours post dosing for each dosing session, and one at a 30-day follow up. The research team is on track to complete data collection from Parkinson's disease patients by the end of February 2023. Data collection is expected to begin in early 2023 for the bipolar study, and in April 2023 for the chronic pain study patients."

Trial status • Back Pain • Bipolar Disorder • CNS Disorders • Pain • Parkinson's Disease

"$SILO PsychedelicNewsBreaks – Silo Pharma Inc. (SILO) Committed to Psilocybin, Anti-Inflammatory Research https://t.co/8ZSkEZX3kt" (@otcdynamics)

"$SILO Silo Pharma Inc. (SILO) Focuses on Psilocybin’s Anti-Inflammatory Properties https://t.co/NKKACXYedv" (@otcdynamics)

Silo Pharma Announces Successful Dosing of Patients Suffering from Parkinson’s Disease in Psilocybin Study (GlobeNewswire) - "Silo Pharma, Inc...today announces that it in conjunction with the University of California San Francisco (UCSF), researchers have successfully dosed patients suffering from Parkinson’s disease. As part of this study, the researchers are collecting blood samples to determine the effects of psilocybin on inflammatory markers of patients who have exhibited signs of Parkinson’s."

Trial status • CNS Disorders • Parkinson's Disease

Silo Pharma Enters into Sponsored Research Agreement with the University of Maryland, Baltimore (GlobeNewswire) - "Company Analyzing Efficacy of Novel Joint Homing Peptide ART-1 for Rheumatoid Arthritis Next steps include targeted approach to delivering Psychedelics including Psilocybin and Ketamine....Silo Pharma, Inc. (OTCQB: SILO), a development stage biopharmaceutical company, today announced that it has entered into a Scientific Research Agreement with the University of Maryland, Baltimore. The main objective of our study is to evaluate the pharmacokinetics of dexamethasone delivered to arthritic rats via liposomes."

Licensing / partnership • Immunology • Rheumatoid Arthritis

Silo Pharma Announces Collaboration with University California San Francisco to study Psilocybin as an Anti-Inflammatory agent in Parkinson’s and Bipolar Patients (GlobeNewswire) - "Silo Pharma...announce that it has entered into a Scientific Research Agreement (SRA) with the University of California San Francisco (UCSF). This SRA will leverage four other clinical trials being planned by the university, to determine the effects of psilocybin on inflammatory markers of patients who have exhibited Parkinson’s, Bipolar disorder, and chronic back pain."

Licensing / partnership • Back Pain • Bipolar Disorder • CNS Disorders • Parkinson's Disease